Business Context and Reporting Period
Company: Jackson Acquisition Company II (JACS)
Reporting Period: Fiscal year ended December 31, 2024 (Inception: September 11, 2024)
Business Type: Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands.
Objective: To effect a merger, share exchange, or asset acquisition with one or more businesses, primarily focusing on healthcare services and technology.
Key Milestone: Consummated its Initial Public Offering (IPO) on December 11, 2024, listing on the NYSE under symbols JACS.U, JACS, and JACS.R.
Key Financial Metrics
| Metric | Value |
|---|---|
| Trust Account Balance | $232,858,478 (Investments held in Trust) |
| Cash Outside Trust | $949,366 |
| Total Assets | $234,005,881 |
| Net Income | $381,082 |
| Operating Expenses | $177,396 |
| Interest Income (Trust) | $558,478 |
| Working Capital | $705,356 |
| Debt / Related Party Loans | $198,024 (Promissory Note to Sponsor) |
Material Changes and IPO Details
The company was formed in September 2024 and had no operations prior to its IPO. The primary financial activity during the period was the capital raise.
- IPO Proceeds: Sold 23,000,000 Units at $10.00 per unit, generating $230,000,000 in gross proceeds. This included the full exercise of the underwriters' over-allotment option (3,000,000 units).
- Private Placement: Simultaneously sold 840,000 Private Placement Units to the Sponsor and underwriters at $10.00 per unit, generating $8,400,000.
- Trust Funding: A total of $232,300,000 was deposited into the Trust Account ($10.10 per public share).
- Transaction Costs: Incurred $5,157,741 in total transaction costs, including a $4,600,000 cash underwriting fee.
Outlook, Risks, and Contingencies
Business Combination Deadline: The company must complete an initial business combination by December 11, 2026 (24 months from IPO). Failure to do so will result in liquidation and redemption of public shares.
Redemption Rights: Public shareholders may redeem shares for a pro-rata portion of the Trust Account (initially $10.10 per share, plus interest). The Sponsor has waived redemption rights for Founder Shares.
Contingent Liabilities:
- Marketing Fee: A deferred fee of up to $9,200,000 (4.0% of gross proceeds) is payable to Roth Capital Partners upon consummation of a business combination.
- Working Capital Loans: The Sponsor and affiliates may loan up to $1,500,000 for transaction costs, convertible into units at $10.00 per unit.
Risks:
- Going Concern: Management believes funds are sufficient for operations for at least one year, but additional financing may be required to complete a business combination.
- Geopolitical: Risks associated with global conflicts (Russia-Ukraine, Israel-Hamas) impacting capital markets.
- Conflicts of Interest: Management has fiduciary duties to other entities (e.g., Jackson Healthcare) which may compete for acquisition targets.
Investor Verification Checklist
- Trust Account Integrity: Verify the $232.86 million balance in the Trust Account and confirm the interest earnings of $558,478.
- Redemption Threshold: Confirm the per-share redemption value remains at or above $10.10, net of taxes and potential withdrawals.
- Related Party Exposure: Review the $198,024 promissory note to the Sponsor and the $10,000/month administrative fee agreement.
- Deferred Fees: Assess the impact of the $9.2 million deferred marketing fee on post-combination liquidity.
- Target Selection: Monitor the company's progress in identifying a healthcare-focused target within the 24-month window.